Pre-Operative fSRS for Brain Metastases
Improving Outcomes in Patients With Metastatic Cancer to the Brain With Pre-Operative Fractionated Radiosurgery (fSRS): A Pilot Study
This pilot study investigates a new approach for patients with metastatic cancer that has spread to the brain (brain metastases) who are already planned to receive both fractionated stereotactic radiosurgery (fSRS) and brain surgery as standard treatment for their condition. Usually, surgery comes first, followed by radiation. However, post-operative radiation can sometimes lead to the cancer returning in the area, spreading to the brain's lining (LMD), or causing side effects from radiation (RN). This study hypothesizes that delivering fSRS before surgery may improve outcomes by enabling more accurate targeting, reducing tumor spillage, and potentially decreasing RN, while improving treatment compliance. The study is specifically testing the sequence of these two standard treatments.
This is a single-arm, prospective study enrolling 12 adult participants (age >18) with 1-5 brain metastases, where one main tumor (between 2.0-5.0 cm diameter) requires surgical resection. Participants will receive fSRS (27 Gy in 3 fractions) approximately one week prior to surgery, as part of the study's approach. Throughout the study, participants will also have regular brain MRI scans to monitor their condition and complete tests to check memory and thinking skills (like the MoCA test) at various points.
The main goal is to see how well the cancer is controlled at the surgery site (called local freedom from progression, or FFP) over 6, 12, 18, and 24 months post-operatively. Secondary outcomes include rates of LMD and RN. Safety (adverse events, toxicities) will be continuously monitored by an independent Data Safety Monitoring Committee (DSMC). Each participant will be in the study for 2 years.
This research aims to provide preliminary data to inform future larger, randomized trials, ultimately improving treatment strategies for patients with metastatic brain cancer.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
New York
-
New York, New York, Yhdysvallat, 10075
- Lenox Hill Hospital, Northwell Health
-
Päätutkija:
- A. Gabriella Wernicke, MD, MS
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Patient is ≥18 years old.
- Radiographic confirmation of 1-5 brain metastases by MRI with contrast obtained within 4 weeks prior to registration. One of these must be an index lesion requiring surgical resection.
- The maximum diameter of the index lesion, as measured on any orthogonal plane (axial, sagittal, coronal) on the post-contrast MRI, must be ≥2.0 cm and ≤5.0 cm.
- Documented pathological diagnosis of active or history of invasive cancer within the past 5 years.
- All brain metastases must be located ≥5 mm from the optic chiasm and outside the brainstem.
- Patient can medically tolerate surgery and fSRS. The treating surgeon must deem the index lesion an appropriate target for safe resection.
- Karnofsky Performance Status (KPS) ≥50 within 14 days prior to registration.
- A negative urine or serum pregnancy test (for individuals of childbearing potential) ≤14 days prior to registration.
- Patient or legally authorized representative provides study-specific informed consent before study entry. For patients treated in the U.S., authorization permitting release of personal health information is also required.
Exclusion Criteria:
- Previous cranial radiotherapy, including whole-brain radiotherapy or stereotactic radiosurgery (SRS), to the planned resection site (index lesion). Repeat radiosurgery to the same location/lesion is not permitted on this protocol.
Note: Prior or current fSRS/SRS to other non-index lesions is allowed.
- Evidence of leptomeningeal disease.
- Any contraindication or inability to undergo MRI with contrast.
- Planned administration of cytotoxic chemotherapy or tyrosine/multi-kinase inhibitors within 3 days prior to, on the day of, or within 3 days after the completion of fSRS.
Note: Chemotherapy and immunotherapy outside of this window are allowed.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Pre-Operative fSRS Followed by Re-Section
This arm consists of all enrolled participants who will receive fractionated stereotactic radiosurgery (fSRS) prior to neurosurgical resection of their brain metastasis. This approach investigates a modified sequence of two standard-of-care treatments for this condition, aiming to evaluate its safety and efficacy. |
Pre-operative fSRS to a dose of 27 Gy in 3 fractions will be delivered to the index lesion every other day. These radiation treatments will be completed within 1 week (+/- 5 days) prior to surgical resection. This is a standard radiation procedure for brain metastases. Surgical removal of the brain metastasis (index lesion) performed after completion of pre-operative fSRS. This is a standard surgical procedure for brain metastases.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Local Freedom from Progression (FFP) within the Resection Cavity
Aikaikkuna: 6, 12, 18, and 24 Months Post-Operative
|
The absence of new nodular contrast enhancement 2 mm or less from the resection cavity. |
6, 12, 18, and 24 Months Post-Operative
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Incidence of Leptomeningeal Disease (LMD)
Aikaikkuna: From post-operative MRI (48-72 hours after surgery) through every 3 months for 2 years
|
Documented incidence of LMD on brain MRI imaging |
From post-operative MRI (48-72 hours after surgery) through every 3 months for 2 years
|
|
Incidence of Radiation Necrosis (RN)
Aikaikkuna: From post-operative (48-72 hours after surgery) through every 3 months for 2 years
|
Documented incidence of RN on brain MRI imaging |
From post-operative (48-72 hours after surgery) through every 3 months for 2 years
|
|
Change in Neurocognitive Function
Aikaikkuna: Baseline, Post-Operative Visit, and Every 3 Months for 2 Years
|
Assessed using the Montreal Cognitive Assessment (MoCA) score |
Baseline, Post-Operative Visit, and Every 3 Months for 2 Years
|
Muut tulostoimenpiteet
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Correlation of Pathologic Information Between Primary Cancer and Resected Brain Metastasis
Aikaikkuna: Between Surgery and Post-Operative Visit
|
Comparison of pathological characteristics of resected brain metastasis with the primary tumor |
Between Surgery and Post-Operative Visit
|
|
Correlation of Extent of Surgical Resection with Survival Outcomes
Aikaikkuna: From study registration until 2 years post-operative or death
|
Evaluation of the Association between extent of surgical resection and Progression-Free Survival (PFS) and Overall Survival (OS) |
From study registration until 2 years post-operative or death
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Shepard MJ, Sheehan JP. The Choice of Postoperative Stereotactic Radiosurgery After Resection of an Isolated Brain Metastasis. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):940. doi: 10.1016/j.ijrobp.2018.05.081. Epub 2019 Oct 24. No abstract available.
- Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1040-1048. doi: 10.1016/S1470-2045(17)30414-X. Epub 2017 Jul 4.
- Palmer JD, Perlow HK, Matsui JK, Ho C, Prasad RN, Liu K, Upadhyay R, Klamer B, Wang J, Damante M, Ghose J, Blakaj DM, Beyer S, Grecula J, Arnett A, Thomas E, Chakravarti A, Lonser R, Hardesty D, Prevedello D, Prabhu R, Elder JB, Raval RR. Fractionated pre-operative stereotactic radiotherapy for patients with brain metastases: a multi-institutional analysis. J Neurooncol. 2022 Sep;159(2):389-395. doi: 10.1007/s11060-022-04073-w. Epub 2022 Jun 25.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- 26-0403
- 23-004 (Muu tunniste: Northwell Health Cancer Institute)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
A formal plan for sharing individual participant data (IPD) has not been developed or approved for this pilot study. Participant confidentiality and privacy are strictly maintained, and study data will be transmitted and stored internally at the Northwell Health Cancer Institute (NHCI) in a de-identified format for statistical analysis and scientific reporting. Results will be disseminated through publications that do not contain identifying information.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .